SOX11i

SOX11i is a first-in-class small molecule inhibitor that targets the transcription factor SOX11, a key oncogenic driver in mantle cell lymphoma (MCL). SOX11 is overexpressed in the majority of MCL cases and is associated with aggressive disease and poor prognosis. SOX11i works by binding to the High Mobility Group (HMG) domain of SOX11, thereby disrupting its interaction with DNA. This inhibition leads to the downregulation of the SOX11-PAX5-CD19 signaling axis, which in turn suppresses B-cell receptor (BCR) signaling pathways, including the phosphorylation of BTK, SYK, and AKT. Preclinical studies have demonstrated that SOX11i can induce apoptosis in MCL cell lines and exhibit cytotoxicity in ibrutinib-resistant patient-derived xenograft (PDX) models. It has also shown synergistic effects when combined with ibrutinib, suggesting its potential to overcome BTK inhibitor resistance in MCL patients.

Other names

SOX11 inhibitorSOX-11 inhibitorSOX 11 inhibitorSOX11 DNA binding inhibitorSOX-11 DNA binding inhibitorSOX 11 DNA binding inhibitor